CO2022005281A2 - Anticuerpos antihemaglutinina y métodos de uso de estos - Google Patents
Anticuerpos antihemaglutinina y métodos de uso de estosInfo
- Publication number
- CO2022005281A2 CO2022005281A2 CONC2022/0005281A CO2022005281A CO2022005281A2 CO 2022005281 A2 CO2022005281 A2 CO 2022005281A2 CO 2022005281 A CO2022005281 A CO 2022005281A CO 2022005281 A2 CO2022005281 A2 CO 2022005281A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- influenza
- methods
- bind
- antihemagglutinin
- Prior art date
Links
- 101710154606 Hemagglutinin Proteins 0.000 abstract 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 3
- 101710176177 Protein A56 Proteins 0.000 abstract 3
- 239000000185 hemagglutinin Substances 0.000 abstract 3
- 208000037798 influenza B Diseases 0.000 abstract 2
- 241000713196 Influenza B virus Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000007501 viral attachment Effects 0.000 abstract 1
- 230000008478 viral entry into host cell Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En la presente descripción se proporcionan anticuerpos monoclonales, o fragmentos de unión al antígeno de estos, que se unen a la proteína hemaglutinina (HA) de influenza B, composiciones farmacéuticas que comprenden los anticuerpos y métodos de uso. Los anticuerpos son útiles para inhibir o neutralizar la actividad del virus de influenza B, y proporcionan así un medio para tratar o prevenir la infección por influenza en seres humanos. En la presente descripción también se proporciona el uso de uno o más anticuerpos que se unen a la HA de influenza B para prevenir el acoplamiento viral y/o la entrada en células huésped. Los anticuerpos pueden usarse profilácticamente o terapéuticamente y pueden usarse solos o en combinación con uno o más de otros agentes o vacunas antivirales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962926914P | 2019-10-28 | 2019-10-28 | |
| US202063094170P | 2020-10-20 | 2020-10-20 | |
| PCT/US2020/057635 WO2021086899A1 (en) | 2019-10-28 | 2020-10-28 | Anti-hemagglutinin antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022005281A2 true CO2022005281A2 (es) | 2022-05-10 |
Family
ID=73498317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0005281A CO2022005281A2 (es) | 2019-10-28 | 2022-04-27 | Anticuerpos antihemaglutinina y métodos de uso de estos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11773156B2 (es) |
| EP (1) | EP4051707A1 (es) |
| JP (1) | JP2022553703A (es) |
| KR (1) | KR20220088446A (es) |
| CN (1) | CN114761428A (es) |
| AU (1) | AU2020374878A1 (es) |
| BR (1) | BR112022007923A2 (es) |
| CA (1) | CA3153944A1 (es) |
| CL (1) | CL2022001067A1 (es) |
| CO (1) | CO2022005281A2 (es) |
| IL (1) | IL292353A (es) |
| WO (1) | WO2021086899A1 (es) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| EP2374818B1 (en) | 2006-06-02 | 2012-12-19 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| HUE029785T2 (en) | 2010-02-08 | 2017-04-28 | Regeneron Pharma | Common mouse light chain |
| WO2013114885A1 (en) | 2012-01-31 | 2013-08-08 | Osaka University | Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same |
| LT3348140T (lt) * | 2012-03-16 | 2021-01-25 | Regeneron Pharmaceuticals, Inc. | Histidinu pakeisti lengvosios grandinės antikūnai ir genetiškai modifikuoti graužikai, išvesti jų gamybai |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN106795216B (zh) * | 2014-02-04 | 2021-04-20 | 抗非特公司 | 可用于被动流感免疫的抗体及其组合物、组合和使用方法 |
| US10639370B2 (en) * | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| CA2942820A1 (en) * | 2014-03-27 | 2015-10-01 | Genentech, Inc. | Anti-influenza b virus hemagglutinin antibodies and methods of use |
| RU2739952C2 (ru) * | 2014-07-15 | 2020-12-30 | МЕДИММЬЮН, ЭлЭлСи | Нейтрализующие антитела к вирусу гриппа b и пути их применения |
| SI3303384T1 (sl) * | 2015-06-01 | 2021-11-30 | Medimmune Llc | Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba |
| WO2016192652A1 (zh) * | 2015-06-03 | 2016-12-08 | 厦门大学 | 抗Flu B的广谱单克隆抗体及其用途 |
-
2020
- 2020-10-28 CN CN202080084529.XA patent/CN114761428A/zh active Pending
- 2020-10-28 WO PCT/US2020/057635 patent/WO2021086899A1/en unknown
- 2020-10-28 JP JP2022523575A patent/JP2022553703A/ja active Pending
- 2020-10-28 AU AU2020374878A patent/AU2020374878A1/en active Pending
- 2020-10-28 US US17/082,375 patent/US11773156B2/en active Active
- 2020-10-28 CA CA3153944A patent/CA3153944A1/en active Pending
- 2020-10-28 IL IL292353A patent/IL292353A/en unknown
- 2020-10-28 EP EP20811191.4A patent/EP4051707A1/en active Pending
- 2020-10-28 BR BR112022007923A patent/BR112022007923A2/pt unknown
- 2020-10-28 KR KR1020227016672A patent/KR20220088446A/ko unknown
-
2022
- 2022-04-27 CO CONC2022/0005281A patent/CO2022005281A2/es unknown
- 2022-04-27 CL CL2022001067A patent/CL2022001067A1/es unknown
-
2023
- 2023-08-21 US US18/453,207 patent/US20240083983A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021086899A1 (en) | 2021-05-06 |
| CA3153944A1 (en) | 2021-05-06 |
| IL292353A (en) | 2022-06-01 |
| US11773156B2 (en) | 2023-10-03 |
| BR112022007923A2 (pt) | 2022-07-26 |
| KR20220088446A (ko) | 2022-06-27 |
| JP2022553703A (ja) | 2022-12-26 |
| CL2022001067A1 (es) | 2023-01-27 |
| AU2020374878A1 (en) | 2022-04-28 |
| US20210171612A1 (en) | 2021-06-10 |
| US20240083983A1 (en) | 2024-03-14 |
| EP4051707A1 (en) | 2022-09-07 |
| CN114761428A (zh) | 2022-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000498A1 (es) | Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920) | |
| CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
| CO2019000968A2 (es) | Anticuerpos anti-virus del zika y métodos de uso | |
| EA201890454A1 (ru) | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств | |
| CL2020001884A1 (es) | Anticuerpos humanos para la hemaglutinina de influenza. | |
| AR116569A1 (es) | Terapia génica para tratar la acidemia propiónica | |
| CL2021002807A1 (es) | Anticuerpos y métodos para el tratamiento de la infección por influenza a | |
| PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| CL2023001462A1 (es) | Anticuerpos ampliamente neutralizantes contra la neuraminidasa de influenza | |
| BR112016015078A2 (pt) | método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica | |
| MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| CO2022005281A2 (es) | Anticuerpos antihemaglutinina y métodos de uso de estos | |
| BR112018067353A2 (pt) | composição farmacêutica e uso de um composto ativo para tratar uma doença causada por vírus do gênero flavivirus em um feto de mamífero | |
| ECSP21039816A (es) | Anticuerpos monoclonales antirrábicos y cóctel de estos | |
| EA201990300A1 (ru) | Антитела к вирусу зика и способы их применения | |
| AR104480A1 (es) | Anticuerpos humanos contra la glicoproteína del virus del ébola | |
| AR103054A1 (es) | Anticuerpos humanos para hemaglutinina influenza | |
| EA202191973A3 (ru) | Человеческие антитела к гликопротеину вируса эбола |